Last reviewed · How we verify
KamRAB - HRIG
KamRAB is a human rabies immunoglobulin (HRIG) that provides passive immunity by supplying antibodies against rabies virus.
KamRAB is a human rabies immunoglobulin (HRIG) that provides passive immunity by supplying antibodies against rabies virus. Used for Post-exposure prophylaxis of rabies in non-vaccinated or incompletely vaccinated individuals.
At a glance
| Generic name | KamRAB - HRIG |
|---|---|
| Sponsor | Kamada, Ltd. |
| Drug class | Human rabies immunoglobulin (HRIG) |
| Target | Rabies virus glycoprotein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
HRIG contains human antibodies specific to rabies virus antigens, particularly the glycoprotein. When administered post-exposure, these antibodies neutralize rabies virus and prevent it from reaching the central nervous system. This passive immunization is used in conjunction with rabies vaccine to provide immediate protection while the body mounts its own immune response.
Approved indications
- Post-exposure prophylaxis of rabies in non-vaccinated or incompletely vaccinated individuals
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Headache
- Anaphylaxis
Key clinical trials
- Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects (PHASE2, PHASE3)
- Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KamRAB - HRIG CI brief — competitive landscape report
- KamRAB - HRIG updates RSS · CI watch RSS
- Kamada, Ltd. portfolio CI